MAM
AMRX icon

Meeder Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Meeder Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-442
Closed -$2.81K – 838
2024
Q2 		$2.81K Hold
442
– – ﹤0.01% 830
2024
Q1 		$2.68K Hold
442
– – ﹤0.01% 702
2023
Q4 		$2.68K Hold
442
– – ﹤0.01% 440
2023
Q3 		$1.86K Hold
442
– – ﹤0.01% 462
2023
Q2 		$1.37K Hold
442
– – ﹤0.01% 482
2023
Q1 		$614 Hold
442
– – ﹤0.01% 565
2022
Q4 		$880 Hold
442
– – ﹤0.01% 742
2022
Q3 		$1K Sell
442
-14,481
-97% -$40.6K ﹤0.01% 1911
2022
Q2 		$47K Hold
14,923
– – ﹤0.01% 881
2022
Q1 		$62K Buy
+14,923
New +$66.1K ﹤0.01% 907
2021
Q4 		– Sell
-16,775
Closed -$88K – 1179
2021
Q3 		$88K Buy
16,775
+273
+2% +$1.37K ﹤0.01% 933
2021
Q2 		$84K Buy
16,502
+14,685
+808% +$83.5K ﹤0.01% 951
2021
Q1 		$10K Buy
+1,817
New +$10.1K ﹤0.01% 1595
2020
Q4 		– Sell
-11,960
Closed -$47K – 1857
2020
Q3 		$47K Sell
11,960
-10,716
-47% -$45.8K ﹤0.01% 966
2020
Q2 		$109K Buy
22,676
+4,406
+24% +$18.1K 0.01% 743
2020
Q1 		$64K Buy
18,270
+4,268
+30% +$18.1K 0.01% 840
2019
Q4 		$67K Sell
14,002
-18,796
-57% -$65.3K ﹤0.01% 929
2019
Q3 		$94K Buy
32,798
+30,228
+1,176% +$105K 0.01% 824
2019
Q2 		$18K Sell
2,570
-9,094
-78% -$93K ﹤0.01% 1268
2019
Q1 		$166K Buy
11,664
+10,347
+786% +$137K 0.01% 580
2018
Q4 		$18K Sell
1,317
-10,093
-88% -$182K ﹤0.01% 1084
2018
Q3 		$253K Buy
11,410
+10,259
+891% +$216K 0.02% 471
2018
Q2 		$18.9K Buy
+1,151
New +$20.2K ﹤0.01% 976

Other funds holding AMRX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Meeder Asset Management's AMRX Position: Q3 2024 in Review

Meeder Asset Management sold out of Amneal Pharmaceuticals (AMRX) in Q3 2024, closing a stake of 442 shares — an estimated $2.81K sold.

Meeder Asset Management first reported a position in AMRX in Q2 2018 and held it in 23 quarters. The position peaked at $253K in Q3 2018. 182 funds tracked by Wall St. Rank hold AMRX as of Q3 2024.

  • Meeder Asset Management reported no remaining Amneal Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Meeder Asset Management sold 442 Amneal Pharmaceuticals shares in Q3 2024, an estimated $2.81K.
  • Meeder Asset Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 23 quarters.
  • Meeder Asset Management's Amneal Pharmaceuticals position peaked at $253K in Q3 2018.
  • 182 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2024.

Based on Meeder Asset Management's 13F filing for Q3 2024, filed 7 Nov 2024.